Oppenheimer Downgrades Aerovate(AVTE.US) to Hold Rating, Cuts Target Price to $3
Oppenheimer analyst Andreas Argyrides downgrades $Aerovate(AVTE.US)$ to a hold rating, and adjusts the target price from $41 to $3.According to TipRanks data, the analyst has a success rate of 44.7%
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
Aerovate | 10-Q: Q2 2024 Earnings Report
Aerovate Therapeutics Shares Are Trading Higher After the Company Announced It Is Exploring Strategic Alternatives.
Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction
Express News | Aerovate Therapeutics - Wedbush Pacgrow Engaged as Exclusive Advisor
Express News | Aerovate Therapeutics Inc - to Conduct Strategic Alternatives Review
Express News | Aerovate Therapeutics to Explore Strategic Alternatives
Aerovate's Catastrophic Year: Failed PAH Drug Trial Leads To Mass Layoffs
Express News | Aerovate Therapeutics Inc - in Connection With Workforce Reduction Plan, Company Estimates That It Will Be Incurring Costs of Approximately $5.6 Mln
Express News | Aerovate Therapeutics Inc: Initiated First Wave of Its Workforce Reduction Plan by Notifying 39 Individuals, or 78% of Company's Workforce
Express News | Aerovate Therapeutics Inc: Under Workforce Reduction Plan, Company Intends That Nearly All of Its Workforce Will Be Terminated in Coming Months
Express News | Aerovate Therapeutics Inc: On June 25, Determined to Implement a Reduction of Company's Workforce
Watching Aerovate Therapeutics; Shares Moving Higher After RA Cap Management Buys 928,110 Shares
Aerovate(AVTE.US) 10% Shareholder Buys US$1.55 Million in Common Stock
$Aerovate(AVTE.US)$ 10% Shareholder RA CAPITAL MANAGEMENT, L.P. purchased 928.11K shares of common stock on Jun 17, 2024 at an average price of $1.67 for a total value of $1.55 million. This transacti
Aerovate Therapeutics Price Target Cut to $2.00/Share From $27.00 by Evercore ISI Group
Guggenheim Downgrades Aerovate Therapeutics to Neutral
Aerovate Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Wells Fargo Downgrades Aerovate Therapeutics to Equal-Weight, Lowers Price Target to $2
A Quick Look at Today's Ratings for Aerovate(AVTE.US), With a Forecast Between $2 to $101
On Jun 18, major Wall Street analysts update their ratings for $Aerovate(AVTE.US)$, with price targets ranging from $2 to $101.Wells Fargo analyst Tiago Fauth downgrades to a hold rating, and adjusts